anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: A stick type makeup cosmetic composition is provided to ensure excellent stability by comprising a core part containing multiple minute lamella spheres and a shell part containing a foundation, a concealer, or blemish balm. CONSTITUTION: A stick type makeup cosmetic composition comprises a core part(2) and a shell part(3). The core part contains multiple minute lamella spheres. The shell part contains a foundation, a concealer, or blemish balm. The multiple minute lamella spheres are prepared by uniformly mixing an active ingredient with a lipid including ceramide, sitosterol, and cholesterol. The average diameter of the multiple minute lamella spheres is 0.05-0.2 micrometers.
PURPOSE: To provide a calcitonin preparation containing a stabilizing agent selected from among an acid and its salt, excellent in thermal stability and photostability, and capable of being preserved for a long period. CONSTITUTION: The calcitonin preparation for the injection contains at least one of an acidic amino acid and its salt (preferably sodium glutamate) preferably in a concentration of 10-50mM. Avian calcitonin (avicatonin) is preferable as the calcitonin used as the active ingredient of the preparation. A solvent for dissolving the calcitonin and the acidic amino acid, and further e.g. a pH- controlling agent, an adsorption-preventing agent, and an isotonic agent may be used. The pH-controlling agent includes citric acid and is preferably added in an amount of 2-10mM. The adsorption-preventing agent includes a nonionic surfactant, and is preferably added in an amount of 0.01-10%(w/v).
Cryoglobulinaemia vasculitis can present with a variety of symptoms and there is limited data on the incidence and presentation of cryoglobulinaemia vasculitis in haemodialysis patients. We report a case of a 63-year-old male who had a series of presentations with rash, visual changes, abdominal pain, weight loss, fevers and digital ischaemia. This is on a background of a congenital single kidney with end-stage renal failure secondary to diabetes and hypertension, receiving haemodialysis for nearly 5 years. He initially experienced a leukocytoclastic vasculitis rash confirmed on skin biopsy, followed by multiple hospital presentations for undifferentiated abdominal pain and fever of unknown source. Jejunal biopsy revealed intestinal vasculitis. His peripheral blood flow cytometry and bone marrow biopsy were consistent with marginal zone lymphoma (indolent subtype, IgM kappa clone). Further testing revealed a type II cryoglobulinaemia consisting of an IgM kappa monoclonal band with polyclonal IgG (cryocrit 5%). A diagnosis of cryoglobulinaemia vasculitis was established and he was treated with pulsed methylprednisolone and rituximab therapy. However, after receiving three doses of rituximab the patient developed a presumed vasculitis-associated pulmonary haemorrhage for which he received treatment with five sessions of plasma exchange. His symptoms resolved and cryocrit reduced to < 1% after his final dose of rituximab. The clinical features of cryoglobulinaemia may be difficult to detect in chronic haemodialysis patients and vigilance is required.
Bacteria and their by-products are the main etiologic factors for pulpal and periapical diseases. The goals of endodontic treatment are to achieve complete disinfection and prevent reinfection in the root canal system and periapical tissues. Sterilization of root canals is limited by the presently available techniques, instruments, irrigants and intracanal medication. Thus, the focus should be on reducing intracanal bacterial populations to levels that are compatible with periapical tissue healing.Because root canal medicaments can come in contact with periapical tissue, in addition to having good antibacterial ability, they must also be biocompatible. In selecting root canal medicaments, it is necessary to consider their therapeutic benefits against their potential cytotoxic effects. Ideal root canal medicaments should have strong antibacterial properties and minimal cytotoxic effect on the host tissues.Globally, plants and their products are used for improving health. Plant extracts contain bioactive compounds like polyphenols, flavonoids, and many other compounds and chemical substances which play important roles to treat diseases. Due to health benefits, phytochemicals from plants generate a lot of interest, demanding further scientific evaluation.Glycyrrhiza which is known as licorice belonging to the Fabaceae, is native to southern Europe and parts of Asia . Glycyrrhizin has been labelled Generally Recognized as Safe (GRAS) by United States Food and Drug Administration (FDA) and has been considered safe for human consumption.Licorice roots have been used as a remedy for cough, laxative, menopausal hot flashes, peptic ulcer, and viral diseases . Licorice contains more than 20 triterpenoids and nearly 300 flavonoids. Among them, glycyrrhizin, 18 β-glycyrrhetinic acid, liquiritigenin, licochalcone A, licochalcone E and glabridin are the main active components which possess antimicrobial, antioxidant and anti-inflammatory activities.Evaluation of intra canal Bacterial levels and species before and after Chemomechanical procedures have been extensively explored by both culture (phenotype) and molecular techniques (genotype) . The latter became choice methods to assess persistent endodontic bacteria because of their high sensitivity and the ability to detect as-yet-uncultivated/difficult-to-culture bacteria.
CF females, 14 - 28 years old, sexually mature, with regular menstrual cycles, not on contraceptive Pill. No intervention is being tested - subjects studied with normal menstrual variations in serum hormone levels. Hypertonic saline may be used to induce sputum production by subjects who are otherwise unable to produce a satisfactory sputum sample.
All subjects will receive the treatment sequence ABC where A=combined oral contraceptive pill (COC), B=COC plus GW273225 and C=GW273225. COC will be administered in two cycles that is, cycle 1 (Days 1-21) and cycle 2 (Days 29-49) of the study. The cycles will be separated by a 7 day washout period. GW273225 will be administered at a dose of one 25 milligram tablet once daily on Days 29-75 of the study.
I have personally experienced evidence that the elastic protein molecules in plants (latex) are similar or identical to the elastic protein molecules in human and animal tissue (elastin). It has been scientifically proven that the human body ceases to manufacture elastin soon after puberty, the gene is "turned off". Therefore, the introduction of the plant protein (latex) may significantly or completely reduce the physiological breakdown characteristic of the aging process. This would positively affect the wrinkling and sagging of our skin, but much more importantly the function of our bodies.      Elastin is found in the walls of our arteries (28-32%), heart tissues, lungs (3-7%), elastic ligaments (50%), tendons (4%), stomach, intestines, skin (2-3%), elastic fibro-cartilage, and others.      When a gene for elastin is missing, "Williams Syndrome" causes premature aging in children. Individuals who have inherited SVAS (supravalvular arterial stenosis) have a mutation of the gene for elastin in one of their chromosomes; therefore for every molecule of normal elastin they produce, they also produce one of abnormal elastin thereby giving their "hybrid elastin" an abnormal structure which leads to a defective elastin protein.      My extensive searches have shown that all research to date has been genetically based, and that all products manufactured to date have been based on the extraction of elastin from animal tissue. I find no indication that anyone has ever considered using the plant-derived elastic molecule to replace the elastic molecule existent in humans and animals.
The invention relates to medicine and pharmacology, more particularly to drugs, and even more particularly to pharmaceutical compositions for treating gastro-oesophageal reflux disease (GORD). The pharmaceutical composition for treating GORD contains at least one proton pump inhibitor (PPI) and at least one prebiotic. Also claimed is a method for treating gastro-oesophageal reflux disease in which it is not necessary to eradicate the presence of H. pylori in order to prevent the risks associated with the translocation of said bacteria from the antrum to the body of the stomach. The composition provides for prevention of the translocation of H. pylori by means of the colonization of the antrum by lactobacilli and the concurrent inhibition of H. pylori during PPI therapy. This makes it possible to dispense with the need to detect the bacteria and carry out a course of eradication therapy. The safety of long-term PPI therapy is increased. Furthermore, the mucous membrane of the stomach does not undergo atrophy; consequently, there is no increase in the risk of stomach cancer.
Do not abruptly discontinue oxycodone and aspirin tablets in a patient physically dependent on opioids. When discontinuing oxycodone and aspirin tablets, in a physically dependent patient, gradually taper the dosage. Rapid tapering of oxycodone and aspirin in a patient physically dependent on opioids may lead to a withdrawal syndrome and return of pain (see DOSAGE AND ADMINISTRATION, DRUG ABUSE AND DEPENDENCE). 

Additionally, avoid the use of mixed agonist/antagonist (i.e., pentazocine, nalbuphine, and butorphanol) or partial agonist (buprenorphine) analgesics in patients who have received or are receiving a course of therapy with a full opioid agonist analgesic, including oxycodone and aspirin tablets. In these patients, mixed agonist/antagonist and partial agonist analgesics may reduce the analgesic effect and/or may precipitate withdrawal symptoms. (see PRECAUTIONS/ Drug Interactions).
Participants in this arm will not take oral omega-3 supplement. They will only receive the Zocular intervention in clinic and the lid wipe and Thealoz eyedrops at home.
Patterns of Strengths and Weaknesses (PSW) methods are widely used for identifying specific learning disabilities (SLDs). Several researchers, however, have reported that the diagnostic accuracy of PSW methods is unacceptably low when strict thresholds were used to identify students with SLDs. We believe these findings give a misleading impression of the magnitude of the diagnostic errors that are likely to arise in PSW assessments. In a simulation study of 10 million cases using a simplified PSW method for demonstration, most of what have been called diagnostic errors were cases in which observed scores and true scores fell on opposite sides of a strict threshold but were still within a buffer zone the size of a typical measurement error. Because small score differences do not result in meaningfully different case conceptualizations, the use of buffer zones reveals that previous estimates of the diagnostic accuracy of PSW methods are misleadingly low. We also demonstrate that diagnostic decisions become increasingly reliable when observed scores are comfortably distant from diagnostic thresholds. For practitioners, we present a flowchart and practical guidelines to improve the accuracy and stability of SLD identification decisions.
Oncology clinician intervention components: 1) a brief training video, 2) For each patient/care partner dyad that is subsequently enrolled onto the study that the clinician cares for, the oncology clinician will receive the results of the patient's GA with targeted management recommendations for identified GA domain impairments. Patient/Care partner dyad intervention components: 1) Communication coaching session; 2) Patient GA results with management recommendations to consider discussing with the oncology team will be provided to care partners and patients.
The goal of this study is to compare a traditional single port expander with a two-port expander for equivalency when used for breast reconstruction following mastectomy. Complication rates that will be tracked include seroma, mastectomy skin flap necrosis, infection, wound dehiscence, need for explantation of the expander. Management of seromas will be compared between the two groups. The investigators hypothesize that the AlloX2 expander will be as effective in achieving the final outcome of completion of the second stage of reconstruction with equal or improved complication rates.

Study Design A prospective 1:1 randomized, single center, open label study will compare the traditional 1- port tissue expander with the AlloX2 2-port expander placed during immediate tissue expander breast reconstruction. Due to the nature of the surgery, the study cannot be blinded. Patients will be followed until completion of expansion and exchange for the permanent implant which typically takes 2 to 3 months. Risks factors that have been previously identified to be associated with increased postoperative complications include smoking, obesity, breast size, diabetes, radiation therapy, and expander fill volume will be identified. The final outcome is completion of expansion and exchange to permanent implant.

Standard operative procedure and postoperative care will be done. Both groups will have the same two external drains placed which is standard operative procedure. Complications will be noted at each postoperative clinic visit and entered into a database. Complication rates will be compared between the two groups and associations with risk factors will be analyzed. There will be no cross-over into the other group in case of reconstructive failure. Treatment failures will be treated in the same fashion in the two groups.
<P>PROBLEM TO BE SOLVED: To provide a method for therapy for B-cell malignancy.  <P>SOLUTION: The method for therapy for B-cell malignancy is provided. The method comprises a process for administration of a therapeutically effective amount of an antagonist anti-CD40 antibody or antigen-binding fragment thereof to a patient in need thereof. The antagonist anti-CD40 antibody or antigen-binding fragment thereof is free of significant agonist activity when the antibody binds a CD40 antigen on a normal human B cell, exhibits antagonist activity when the antibody binds a CD40 antigen on a malignant human B cell, and can exhibit antagonist activity when the antibody binds a CD40 antigen on a normal human B cells. Antagonist activity of the anti-C antibody or antigen-binding fragment thereof beneficially inhibits proliferation and/or differentiation of malignant human B cells.  <P>COPYRIGHT: (C)2008,JPO&INPIT
The invention discloses a method of extracting lentinan from waste lentinus edodes stem and belongs to the technical field of extraction of the lentinan. In the method, beet is subjected to fermentation to obtain fermentation liquid. The fermentation liquid then is subjected to pressure-reduced concentration, wherein the concentrated fermentation liquid is used for performing extraction to a mixed fermentation substance of the lentinus edodes stem and wheat instead of organic solvents, such as chloroform, n-butyl alcohol and the like, to obtain a concentrated extraction liquid. The concentrated extraction liquid then is filtered, sterilized and refrigerated to obtain the lentinan. An embodiment proves that the method is simple in operation. With the waste lentinus edodes stem as the raw material, the method achieves fully utilization of resources and increases extraction rate, is free of addition of harmful organic solvents during extraction, greatly maintains bio-activity of active components and is environment-friendly.
OBJECTIVE: The increased amplitude of ictal activity is a common feature of epileptic seizures, but the determinants of this amplitude have not been identified. Clinically, ictal amplitudes are measured electrographically (using, e.g., electroencephalography, electrocorticography, and depth electrodes), but these methods do not enable the assessment of the activity of individual neurons. Population signal may increase from three potential sources: (1) increased synchrony (i.e., more coactive neurons); (2) altered active state, from bursts of action potentials and/or paroxysmal depolarizing shifts in membrane potential; and (3) altered subthreshold state, which includes all lower levels of activity. Here, we quantify the fraction of ictal signal from each source.
METHODS: To identify the cellular determinants of the ictal signal, we measured single cell and population electrical activity and neuronal calcium levels via optical imaging of the genetically encoded calcium indicator (GECI) GCaMP. Spontaneous seizure activity was assessed with microendoscopy in an APP/PS1 mouse with focal cortical injury and via widefield imaging in the organotypic hippocampal slice cultures (OHSCs) model of posttraumatic epilepsy. Single cell calcium signals were linked to a range of electrical activities by performing simultaneous GECI-based calcium imaging and whole-cell patch-clamp recordings in spontaneously seizing OHSCs. Neuronal resolution calcium imaging of spontaneous seizures was then used to quantify the cellular contributions to population-level ictal signal.
RESULTS: The seizure onset signal was primarily driven by increased subthreshold activity, consistent with either barrages of excitatory postsynaptic potentials or sustained membrane depolarization. Unsurprisingly, more neurons entered the active state as seizure activity progressed. However, the increasing fraction of active cells was primarily driven by synchronous reactivation and not from continued recruitment of new populations of neurons into the seizure.
SIGNIFICANCE: This work provides a critical link between single neuron activity and population measures of seizure activity.
Subcutaneous Infusion Administration

The average daily dose of Desferal is usually between 20 and 60 mg/kg. In general patients with serum ferritin level below 2,000 ng/mL require about 25 mg/kg/day. Patients with serum ferritin level between 2,000 and 3,000 ng/mL require about 35 mg/kg/day. Patients with higher serum ferritin may require up to 55 mg/kg/day. It is not advisable to regularly exceed an average daily dose of 50 mg/kg/day except when very intensive chelation is needed in patients who have completed growth. If ferritin levels fall below 1,000 ng/mL, the risk of Desferal toxicity increases; it is important to monitor these patients particularly carefully and perhaps to consider lowering the total weekly dose. The doses specified here are the average daily doses. Since most patients use Desferal less than 7 days a week, the actual dose per infusion usually differs from the average daily dose; e.g., if an average daily dose of 40 mg/kg/day is required and the patient wears the pump 5 nights a week, each infusion should contain 56 mg/kg.

Slow subcutaneous infusion using a portable, light-weight infusion pump over a period of 8 to 12 hours is regarded as effective and especially convenient for ambulatory patients but may also be given over a 24-hour period. Desferal should normally be used with the pump 5 to 7 times a week. Desferal is not formulated to support subcutaneous bolus injection.

Intravenous Administration

Desferal can be administered intravenously if needed in patients with intravenous access.

The recommended dose of Desferal in adults is 40 mg/kg/day to 50 mg/kg/day over 8 hours to 12 hours at a rate of up to 15 mg/kg/hour for 5 days to 7 days per week. Maximum dose is 60 mg/kg/day.

The recommended dose of Desferal in pediatric patients is 20 mg/kg/day to 40 mg/kg/day over 8 hours to 12 hours for 5 days to 7 days per week. The maximum recommended daily dose is 40 mg/kg/day until growth (body weight and linear growth) has ceased.

In case of missed doses, Desferal may be administered prior to or following same day blood transfusion (for example, 1 gram over 4 hours on the day of transfusion); however, the contribution of this mode of administration to iron balance is limited. Desferal should not be administered concurrently with the blood transfusion as this can lead to errors in interpreting side effects such as rash, anaphylaxis and hypotension.

Intramuscular Administration

If given intramuscularly, the recommended dose of Desferal is 500 mg to 1,000 mg per day. The maximum recommended daily dose is 1,000 mg per day.
PURPOSE: To obtain the subject agent, having excellent antiactive oxygen actions and remarkably reduced in malodor and color by roasting a vegetable oil seed and/or embryos, then carrying out the fermentation treatment, adding a vegetable oil, etc., thereto and treating the resultant substance according to a specific method. CONSTITUTION: This agent is obtained by roasting a vegetable seed (e.g. barley or soybean) and/or embryos (e.g. rice bran or wheat embryo), then carrying out the fermentation treatment with KOJI (malted rice) mold, subsequently adding a vegetable oil and/or vegetable seeds, e.g. sesame oil or powdered green tea thereto, extracting the resultant raw material substance with a polar solvent (preferably hydrous ethanol) and further washing the prepared extract solution with a nonpolar solvent (e.g. n- hexane) and subsequently treating the washed substance with active carbon (preferably standard charcoal). The treatment with the active carbon is preferably performed by using the active carbon in an amount of 2-3wt.% based on the raw material substance.  Furthermore, the objective agent is preferably used in 20-500mg dose at a time and daily used once to several times so as to provide 20-1000mg total daily dose.
The present disclosure provides a smart purchasing system for a plurality of medical supplies, which is configured to automatically execute a purchasing operation. The smart purchasing system for the medical supplies includes a medical institution and a medical management platform. The medical institution includes the medical supplies and generates a plurality of consumption information corresponding to the medical supplies. The medical management platform is signally connected to the medical institution, and includes an inventory water stage and a threshold water stage corresponding to one of the medical supplies. The medical management platform adjusts the inventory water stage according to the consumption information and confirms whether the inventory water stage is lower than the threshold water stage. When the inventory water stage is lower than the threshold water stage, the medical management platform establishes a purchase information corresponding to the medical supply and sends the purchase information to a supplier. The supplier carries out the purchasing operation for the medical institution according to the purchase information. Therefore, it is favorable for monitoring an inventory of the medical supplies so as to save the time of manual inventory and replenish immediately.
Upper and lower extremity surgery is particularly suited to regional anaesthesia. Peripheral nerve blocks (PNB) can produce surgical anaesthesia in less than 30 minutes. PNBs have been associated with early outcome improvements when surgery is conducted awake or with light sedation. These benefits include reduced nausea and vomiting, improved patient satisfaction and accelerated recovery room and hospital discharge. PNBs can also provide effective postoperative pain relief.

Currently there is no globally accepted standard by which to assess when surgical anaesthesia has been achieved following administration of PNBs. The decision as to when adequate surgical anaesthesia has been achieved and when surgery can then proceed is usually left to the discretion of the anaesthetist. The anaesthetist can assess nerve blockade though several motor and sensory function tests: cold, heat, touch and pinprick sensitivity. Several scoring systems have been described using these tests to estimate when surgical anaesthesia has been achieved but none have been independently validated outside of the original studies in which they have been described.